PAK2 and familial pancreatic carcinoma: In the GSE15471 (Figure 4E), GSE62165 (Figure 4F), GSE62452 (Figure 4G), and GSE71729 (Figure 4H) cohorts, the Wilcoxon test showed statistically significant differences in PAK2 expression between pancreatic cancer and normal individuals, with elevated expression of PAK2 in pancreatic cancer patients.